Aureka Biotechnologies uses integrated digital biology and generative AI to accelerate the discovery of high-value protein therapeutics. Their platform enables rapid "Generate-Test-Learn-Optimize" cycles, significantly increasing discovery efficiency for immunotherapies. This approach aims to deliver better drugs faster and at a lower cost for challenging disease targets.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NCFounders
Product
Problem
Many diseases remain difficult to treat due to the limitations of current drug discovery methods in identifying effective protein therapeutics for challenging targets. Traditional therapeutic development is often slow and expensive, hindering progress in addressing unmet medical needs.
Solution
Aureka Biotechnologies leverages high-throughput digital biology and generative AI to accelerate the discovery of protein therapeutics, particularly for diseases with previously unattainable targets. By integrating scalable digital biology with AI, Aureka significantly streamlines the "Generate-Test-Learn-Optimize" cycle, enabling rapid iteration and optimization of therapeutic candidates. This approach facilitates the identification of better drug candidates while reducing the time and cost associated with traditional drug discovery processes. Aureka's technology platform ecosystem is designed for immunotherapeutic discovery, allowing for the development of new therapeutics for previously inaccessible targets and mechanisms.
Target Audience
Aureka Biotechnologies primarily targets pharmaceutical companies and research institutions seeking to accelerate their drug discovery efforts and develop novel protein therapeutics for challenging diseases.
Features
- Integrated digital biology and AI platform for rapid therapeutic discovery
- High-throughput screening and analysis of protein therapeutics
- Generative AI models for designing and optimizing drug candidates
- Scalable "Generate-Test-Learn-Optimize" iteration cycles
- Identification of novel targets and mechanisms for therapeutic intervention